Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.
von dem Borne, P
AffiliationEurocord, Hopital Saint Louis, Paris, FranceMonacord, Centre Scientifique de Monaco, Monaco
MetadataShow full item record
AbstractA disease risk index (DRI) has been defined for stratifying heterogeneous cohorts of patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). This index defines 4 distinct groups with different outcomes, dividing patients by disease type and status and considering cytogenetics for acute myeloid leukaemia and myelodysplastic syndromes (MDS). Recently, the DRI has been refined to include rare diseases and improve MDS stratification by blast percentage and response to prior therapy. Previous reports on DRI include only a small number of UCBT recipients. The current study aims to determine the applicability of the DRI for patients undergoing unrelated cord blood transplantation (UCBT). We retrospectively analysed 2530 adults receiving UCBT between 2004 and 2014. Diagnosis was acute leukaemia (AL) in 66% of the cases. Overall survival (OS) at 2 years was 56 ± 3% for patients with low DRI (n = 352), 46 ± 1% for intermediate DRI (n = 1403), 28 ± 2% for high (n = 489) and 20 ± 4% for very high DRI (n = 109) (P < 0·001). In the multivariate model, DRI remained an independent risk factor for OS. Similar findings were observed for PFS and DRI. Our results show the applicability of DRI for stratifying UCBT recipients and confirm the prognostic value of this simple and robust tool in this setting.
CitationEvaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. 2017, Br J Haematol
JournalBritish Journal of Haematology
- Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.
- Authors: Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W
- Issue date: 2017 Jun
- Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China.
- Authors: Li XY, Sun X, Chen J, Qin MQ, Luan Z, Zhu YP, Fang JP
- Issue date: 2018 Feb
- Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
- Authors: Koh H, Nakamae H, Hagihara K, Nakane T, Manabe M, Hayashi Y, Nishimoto M, Umemoto Y, Nakamae M, Hirose A, Inoue E, Inoue A, Yoshida M, Bingo M, Okamura H, Aimoto R, Aimoto M, Terada Y, Koh KR, Yamane T, Ohsawa M, Hino M
- Issue date: 2011 Apr 10
- Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis.
- Authors: Chen YH, Xu LP, Liu DH, Chen H, Zhang XH, Han W, Wang FR, Wang JZ, Wang Y, Huang XJ, Liu KY
- Issue date: 2013 Jul
- Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
- Authors: Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kroger N, Rocha V
- Issue date: 2011 Jan